جامعة عين شمس ۲۰۰۷

PREVALENCE OF HYPERHOMOCYSTEINEMIA IN TYPE † DIABETIC PATIENTS AND ITS RELATION TO THE DIFFERENT THERAPEUTIC MODALITIES FOR DIABETES

Thesis
Submitted for the Partial Fulfillment of
Master Degree In "Internal Medicine"

By

Nahla Salah El Den Sherif Omar Sherif (M.B, B.Ch)

Supervised By

Prof. Dr. Hussein Abd El Haye El Oraby

Professor of Internal Medicine and Endocrinology Faculty of Medicine – Ain Shams University

Dr. Manal Mohamed Abo Shady

Lecturer of Internal Medicine and Endocrinology Faculty of Medicine – Ain Shams University

Dr. Mona Mohamed Abd El Salam

Lecturer of Internal Medicine and Endocrinology Faculty of Medicine – Ain Shams University ۲.,۱

Acknowledgement

First, thanks are all to **ALLAH** for blessing this work until it has reached its end as a part of his generous help throughout my life.

I have the greatest pleasure to express my thanks and profound gratitude to **Professor Dr.Hussein Abd El-Haye El-Oraby**, Professor of Internal Medicine and Endocrinology, Faculty of Medicine, Ain-Shams University, to whom I am deeply indebted for encouraging me to develop this work, and for the valuable supervision and continuous help, he has given me since I started this work.

I wish to express my thanks to **Dr.Manal Mohamed Abo-Shady**, Lecturer of Internal Medicine and Endocrinology, Faculty of Medicine, Ain-Shams University, for her care and advice.

I sincerely appreciate all the encouragement, unlimited help and endless support given by **Dr.Mona Mohamed Abd El-Salam**, Lecturer of Internal Medicine and Endocrinology, Faculty of Medicine, Ain-Shams University, to whom I am indebted for her valuable instructions, inspiring guidance and great assistance throughout this work.

I would like to express my utmost thanks to **Dr.Ahmed Mohamed Abd El-Salam**, Fellow of Cardiology Ain-Shams University, who gave me much of his time throughout this work.

I would like also to express my thanks to **Dr.Radwa Nabil** Assistant Lecturer of Ophthalmology, Faculty of Medicine, Ain-Shams University for her help.

Finally, I want to express my appreciation and gratitude to my parents and especial thanks to my sister **Heba**, also to my friends and

LIST OF CONTENTS

Title Page No.	
Introduction	1
Aim of the work	٣٣
Review of literature	
o Non traditional risk factors & macrovascul complications in type 7 diabetes mellitus	
o Homocysteine	٣٦
O Hyperhomocysteinemia and its relation to ty d. m.	•
Subjects and methods	۸۳
Results	٩ ٤
Discussion	170
Summary	1 ٤ ٤
Conclusion	1 ٤٨
Recommendations	1 £ 9
References	101
Arabic summary	

colleagues. As, without their help this work would have not been accomplished.

LIST OF TABLES

Table No.	Details	Page No.
١	Comparison between studied groups as regard gender by using chi-square test.	١
۲	Comparison between the studied groups as regard age, weight, duration of type \(^{\gamma}\) DM, systolic and diastolic blood pressures by using one way ANOVA test.	1.1
٣	Comparison between the studied groups as regard fundus examination results by using chi-square test.	1.7
٤	Descriptive table for ECG and echo findings of the studied groups.	1.7
٥	Descriptive table for the laboratory data of the studied groups.	1.5
٦	Comparison between the diabetic cases (\(\frac{1}{\cdot}\)) and control group (\(\frac{1}{\cdot}\)) as regard homocysteine level by using unpaired t-test.	١٠٤
٧	Comparison between the diabetic cases (\(\frac{1}{\cdot}\)) and control group (\(\frac{1}{\cdot}\)) as regard vitamin B\(\frac{1}{\cdot}\) level by using unpaired t-test.	١٠٤
٨	Comparison between the metformin group and other groups as regard homocysteine level by using unpaired t-test.	1.0
٩	Comparison between sulfonylurea group versus insulin and control groups as regard homocysteine level by using unpaired t-test.	١٠٦
١.	Comparison between insulin group and control group as regard homocysteine level by using unpaired t-test.	1.4
))	Comparison between the metformin group versus other groups as regard vitamin B ^{\gamma} level by using unpaired t-test.	1.4
١٢	Comparison between sulfonylurea group versus insulin and control groups as regard vitamin BY level by using	١٠٨

Table No.	Details	Page No.
	unpaired t-test.	
١٣	Comparison between insulin group and control group as regard vitaminB ^{\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\}	١٠٨
	I	

LIST OF TABLES (Cont...)

Table No.	Details	Page No.
١٤	Correlation between homocysteine level versus different laboratory and clinical data among metformin group by using correlation co-efficient test.	1.9
10	Correlation between homocysteine level versus different laboratory and clinical data among sulfonylurea group by using correlation co- efficient test.	11.
١٦	Correlation between homocysteine level versus different laboratory and clinical data among insulin group by using correlation co-efficient test.	111
١٧	Correlation between homocysteine level versus different laboratory and clinical data among the 'type 'diabetic patients by using correlation co-efficient test.	۱۱۲
١٨	Correlation between homocysteine level versus different laboratory and clinical data among control group by using correlation co-efficient test.	117
19	Relation between homocysteine level versus echo among the 7. type 7 diabetic patients by using unpaired t-test.	115
۲.	Relation between homocysteine level versus gender among the 'type 'diabetic patients by using unpaired t-test.	111
۲۱	Relation between homocysteine levels versus gender among the control group by using unpaired t-test.	110
**	Relation between vitamin Byr level versus gender among the retype r diabetic patients by using unpaired t-test.	110
77	Relation between vitamin Byr level versus gender among the control group by using unpaired t-test.	117
7 £	Relation between homocysteine level and vitamin Byr level versus fundus findings among insulin group by using unpaired t-test.	١١٦
۲٥	Correlation between vitamin BYY level versus age among the Y type Y diabetic patients by using correlation coefficient test.	117

LIST OF FIGURES

Figures in Review:

Figure No.	Details	Page No.
١	Homocysteine metabolism	٣٧
۲	Species of homocysteine in plasma.	٤١
٣	Factors influencing total homocysteine level.	٤٤
	s in Results:	
Figure No.	Details	Page No.
١	Shows that total cases of type \(^{\text{total diabetes}}\) diabetes had higher level of homocysteine compared to control group.	. 114
4	Shows that total cases of type ⁷ diabetes had lower level of vitamin B ¹ compared to control group.	. 114
٣	Represents a comparison between all groups as regard homocysteine level. It shows that metformin group had the highest level of homocysteine compared to sulfonylurea, insulin and control groups.	. 119
٤	Represents a comparison between all groups as regard vitamin B'' level. It shows that metformin group had the lowest level of vitamin B'' compared to other groups	. 119
ð	Represents a positive correlation between homocysteine level and HbA\c\% among patients of metformin group	. 17.
٦	Represents a positive correlation between homocysteine level and systolic blood pressure among patients of metformin group.	. 17.
٧	Represents a positive correlation between homocysteine level and diastolic blood pressure among patients of metformin group.	. 171

Figure No.	Details	Page No.
٨	Represents a positive correlation between homocysteine level and LDL-C among patients of metformin group	171
	iii	

LIST OF FIGURES (Cont...)

Figures in Results (Cont...):

Figure No.	Details	Page No.
٩	Represents a positive correlation between homocysteine level and systolic blood pressure among patients of sulfonylurea group.	177
١.	Represents a positive correlation between homocysteine level and diastolic blood pressure among patients of sulfonylurea group.	177
11	Represents a positive correlation between homocysteine level and LDL-C among patients of insulin group	١٢٣
١٢	Shows an inverse correlation between homocysteine levels versus vitamin B ^{\gamma\gamma} level among all groups	١٢٣
١٣	Shows that males had a higher level of homocysteine than females among the studied cases.	١٢٤
1 £	Shows that male had a lower level of vitamin BYY than females among the studied cases.	١٢٤

LIST OF ABBREVIATION

ACEI Angiotensin converting enzyme inhibitor.

ADMA Asymmetric dimethyl arginine.

AT Alpha tocopherol.

BHMT Betaine homocysteine methyltransferase.

BMI Body mass index.

BMD Bone Mineral Density

BNP B-type natriuretic peptide.

CAD Coronary artery disease.

CAN Cardiac autonomic neuropathy.

CBS Cystathionine-β synthase.

CGL Cystathionine-δ lyase.

CGL Cystathionine-δ lyase.
CHD Coronary heart disease.
CRF Chronic renal failure.
CRP C-reactive protein.
CVD Cardiovascular disease.

DM Diabetes mellitus.

E gr.\(^\) Early growth response gene-\(^\) eNOS Endothelial nitric oxide synthase.

ESRD End-stage renal disease.

FFAs Free fatty acids.

FMD Flow mediated dilatation. **FPG** Fasting plasma glucose.

FPIA Fluorescence polarization immunoassay.

GDM Gestational diabetes mellitus.
GFR Glomerular filtration rate.

Hcv Homocysteine.

HDL High-density lipoprotein.HMG CoA Hydroxy methyl glutryl Co A.

HOPE Heart Outcome Prevention Evaluation.

ICAM Intercellular adhesion molecule.

IFG Impaired fasting glucose.
 IGF-¹ Insulin growth factor-¹.
 IGT Impaired glucose tolerance.
 IHD Ischemic heart disease.

IL-\(\frac{1}{2}\) Interieukin-\(\frac{1}{2}\).

IMT Intima-media thickness.IRS Insulin resistance syndrome.LDL Low-density lipoprotein.

Lp (a) Lipoprotein (a).

MAT Methionine adenosyltransferase.

MeTHF Methyltetrahydrofolate.MI Myocardial infarction.

MICRO-HOPE Microalbuminuria, Cardiovascular and Renal Outcomes in HOPE.

MNC Mononuclear cells
MS Methionine synthase.
NAC N-acetylcysteine.
NO Nitric oxide.

NOS Nitric oxide synthase.

NPDR Non-proliferative diabetic retinopathy.

OC Oral contraceptives.

PAI-\ Plasminogen activator inhibitor type \. PDR Proliferative diabetic retinopathy.

PPAR Peroxisome proliferators-activated receptors.

SAH S-adenosylhomocysteine. SAM S-adenosylmethionine.

TF Tissue factor.

tHcy Total homocysteine.

TGF-βTransforming growth factor β.TNF-αTumor necrosis factor α.TZDsThiazolidinediones.

UKPDS United Kingdom Prospective Diabetes Study.

VCAM Vascular cell adhesion molecule.
VLDL Very low density lipoprotein.

vWF von Willebrand factor.

INTRODUCTION

Diabetes mellitus has been defined as a coronary heart disease risk equivalent. Therefore, there has been a major focus on preventing cardiovascular disease and controlling cardiovascular disease risk factors in the diabetic patient, and more aggressive treatment goals have been proposed for diabetic patients (*American Diabetes Association*, 7 · · 7).

Traditional risk factor such as hypertension, dyslipidemia and poor metabolic control has been well identified in type \(^{\text{t}}\) diabetic patients. However, they do not fully explain the acceleration in macro-vascular disease in those patients (*Hoogeveen et al.*, \(^{\text{t}} \cdot \cdot \cdot a)\). Thus, non traditional risk factors came into focus.

Hyperhomocysteinemia is an independent risk factor for cardiovascular disease (*Guilliams*, $r \cdot \cdot \cdot t$). It has been identified also as a modest predictor and stroke risk in healthy population (*The Homocysteine Studies Collaboration*, $r \cdot \cdot r$), and even correlated with the angiographic extent of coronary artery disease (*Bozkurt*, $r \cdot \cdot t$).

Diabetes mellitus is associated with impaired homocysteine metabolism which might contribute to endothelial- myocyte dysfunction in the heart of diabetic patients (*Tyagi et al.*, **·•**b*). In addition, metformin; a key treatment option in type * diabetes, decreases vitamin B **

Introduction

levels and subsequently increases homocysteine levels (*Wulffele et al.*, $r \cdot r$). On the contrary, sulfonylureas were associated with lower serum levels of homocysteine when compared to diet and physical activity alone (*Hellgren et al.*, $r \cdot r \cdot r$).

AIM OF THE WORK

To study the prevalence of hyperhomocysteinemia among type ⁷ diabetic patients receiving different anti-diabetic therapies.

NON TRADITIONAL RISK FACTORS & MACROVASCULAR COMPLICATIONS IN TYPE Y DIABETES MELLITUS

Diabetes mellitus is defined as a group of metabolic diseases characterized by hyperglycemia due to defects in insulin secretion, insulin action or both (American Diabetes Association, $\gamma \cdot \cdot \gamma$).

Several distinct types of diabetes mellitus (DM) exist and are caused by a complex interaction of genetics, environmental factors, and life-style choices. Depending on the etiology of the DM, factors contributing to hyperglycemia may include reduced insulin secretion, decreased glucose utilization, and increased glucose production. The metabolic dysregulation associated with DM causes secondary pathophysiological changes in multiple organ systems that impose burden on the individual with diabetes and on the health care system. In the United States, DM is the leading cause of end-stage renal disease (ESRD), non traumatic lower extremity amputations, and adult blindness. With an increasing incidence worldwide, DM will be a leading cause of morbidity and mortality for the foreseeable future (Gillam & Landsberg, ****).

- **I. Type \ diabetes** (β-cell destruction, usually leading to absolute insulin deficiency):
 - **A.** Immune-mediated.